We have demonstrated previously that iNOS gene therapies delivered intratumorally produce an impressive therapeutic benefit9, 10, 11, 12, 19 and described reporter gene expression when the Luciferase gene was delivered systemically using RALA,1 but this is the first description of systemic RALA-mediated therapeutic transgene delivery and the first description of systemically delivered iNOS for cancer gene therapy. Here, NOS2 is linked to cancer.